Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics
Purpose of review Bromodomain and extraterminal domain (BET) proteins are evolutionarily conserved, multifunctional super-regulators that specifically recognize acetyl-lysine on histones and other proteins controlling gene transcription. Several studies show that small molecules targeting these regulators preferentially suppress the transcription of cancer-promoting genes. Consequently, several BET inhibitors reached clinical trials and are in various stages for different kind of malignancies. In this review, we provide a concise summary of the molecular basis and preliminary clinical outcomes of BET inhibitors as anti...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

Targeting SUMOylation in cancer
Purpose of review In the article, we focus on the role of SUMOylation in tumorigenesis and cancer-related processes, including Epithelial–mesenchymal transition (EMT), metastasis, resistance to cancer therapies, and antitumor immunity. Clinical perspective on small ubiquitin-like modifier (SUMO) inhibitors will be discussed. Recent findings SUMOylation regulates multiple important biologic functions including gene transcription, DNA damage repair, cell cycle, and innate immunity. The SUMO pathway enzymes are usually elevated in various cancers and linked with cancer progression and poor clinical outcomes f...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

New horizons in early drugs development in solid cancers
Purpose of review Drug development is the process of bringing new anticancer agents into clinical practice. From the basic research to clinical research each step is essential and intimately linked. The aim of this review is to describe emerging preclinical models and to provide an overview of selected drugs recently developed in oncology. Recent findings Preclinical models reproducing human immune-tumor interactions, 3D cell cultures and microfluidic platforms are of great interest for the development of immunotherapies and combination therapies and offer the opportunity to better understand the interplay betwe...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

Challenges adopting next-generation sequencing in community oncology practice
This article, based on the authors’ experience in community oncology practice and summary of literature, describes these challenges so strategies can be developed to address these challenges to improve patient outcomes. (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics
Purpose of review Targeting Prostate-Specific Membrane Antigen (PSMA) has paved the way for personalized medicine in prostate cancer (PCa) patients. This review aims to highlight the role of PSMA targeting antibodies in PCa, for diagnostic and therapeutic purposes. Recent findings PSMA Positron Emission Tomography/Computed Tomography has been a game changer in the diagnosis of PCa in the recent decade. Two anti-PSMA monoclonal antibodies have been studied in PCa: 7E11-C35 (limited use) and J591. J591 antibody was used for diagnostic purposes coupled with different radionuclides. Most importantly, it was combined...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

Targeted radionuclide therapy: an emerging field in solid tumours
Purpose of review Targeted radionuclide therapy (TRNT) is characterized by systemic administration of radiolabelled drugs, targeting specific molecular alterations expressed on the tumour cells. Small molecules, labelled with β- or α- emitting radioisotopes, are used to deliver radiation directly to the tumour sites. Pretreatment imaging to visualize whole body biodistribution of the target, using the same drugs labelled with positron or γ-emitting radionuclides, completes the concept of theranostic. This review will briefly summarize the current clinical research findings and applications of TRNT in s...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

New developments in rare vulvar and vaginal cancers
Purpose of review To provide the latest insight on the rare vulvar and vaginal malignancies, able to impact on clinical practice, and to outline new potential research developments. Recent findings Many efforts are being made to produce technical and scientific advances in the fields of vulvar and vaginal carcinoma, including imaging work-up, interventional procedures and minimally invasive surgical approach, as well as molecular profiling and identification of new target treatments. Summary In the evaluation of lymph node status, ultrasound has demonstrated promising results because of high predictive va...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Novel next-generation sequencing-based methodologies to characterize the mutational consequences of (prenatal) chemotherapy exposure in noncancerous tissue
Purpose of review Although chemotherapeutics are considered as genotoxins for decades, their exact mutagenic impact on the genome of cancerous and normal cells of cancer patients was unknown for a long time. However, this knowledge is necessary to understand the long-term side effects of chemotherapy. A particular condition represents pregnant cancer patients being treated with chemotherapy. Since certain chemotherapeutics can cross the placenta, concerns exist about possible mutational effects on the fetus’ genome with potential long-term health consequences. Recent findings Recent advances of next-genera...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

New imaging modalities to distinguish rare uterine mesenchymal cancers from benign uterine lesions
Purpose of review Uterine sarcomas are rare and are often challenging to differentiate on imaging from benign mimics, such as leiomyoma. As functional MRI techniques have improved and new adjuncts, such as machine learning and texture analysis, are now being investigated, it is helpful to be aware of the current literature on imaging features that may sometimes allow for preoperative distinction. Recent findings MRI, with both conventional and functional imaging, is the modality of choice for evaluating uterine mesenchymal tumors, especially in differentiating uterine leiomyosarcoma from leiomyoma through valida...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique
Purpose of review During the last few years there have been important advances in our understanding of endometrial cancer biology, staging, and therapy. In this article, we discuss updates and controversies in the treatment of nonendometrioid endometrial carcinoma (non-EEC), with an emphasis on the role of sentinel lymph node (SLN) biopsy. Recent findings Lymph node involvement is an important factor in determining prognosis and guiding adjuvant therapy in endometrial carcinoma. SLN biopsy has emerged as a less morbid alternative to lymphadenectomy in surgical staging, and it has generally gained acceptance in t...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Immunotherapy in rare ovarian cancer
Purpose of review Ovarian cancer (OC) is a heterogeneous disease and a mounting body of evidence shows that a ‘one-size-fits-all’ approach is obsolete. Differences in epidemiology, tumor biology, genetic profiles and treatment responses of these different types necessitate a tumor and patient-specific approach. Ninety percentage consists of epithelial OC with 70% being high-grade serous OC. The other rarer subtypes are low-grade serous (5%), clear cell (12%), endometrioid (11%) and mucinous carcinoma (3%). The remaining 10% are nonepithelial rare OCs: germ cell (3%) and sex-cord stromal tumors (7%). Rece...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Importance of guidelines and networking for the management of rare gynecological cancers
The objective of our paper is to highlight the need for such recommendations, to reinforce strategies in place and to promote the creation of multidisciplinary networks to provide the most appropriate care to patients and to improve it. Recent findings Gynecological rare cancers are not that rare since they represent around 50% of all gynecological cancers. Surgery remains the cornerstone of management for all subtypes. Apart from malignant ovarian germ-cell tumors for which conventional chemotherapy was proven to be efficient, response to standard systemic treatment for other gynecological cancers are disappointing...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Ten steps to establish a national centre for gestational trophoblastic disease
Purpose of review Gestational trophoblastic disease (GTD) is a group of heterogeneous disorders characterized by abnormal proliferation of trophoblastic tissue. GTD is a rare disease that is curable in the vast majority of patients when managed appropriately. The aim of the review is to discuss the important steps necessary to establish a center of excellence for GTD. Recent findings Care of patients with a rare disease is complicated by lack of strong evidence, scattering of patients across the country and limited expertise of medical professionals. The establishment of a center of excellence requires awareness...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Editorial: The challenge of treating and investigating rare gynaecologic cancers
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: GYNECOLOGIC CANCER: Edited by Frédéric Amant and Christianne Lok Source Type: research

Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up
Purpose of review The aim of this study was to highlight the diagnostic and management challenges of primary vitreoretinal lymphoma (PVRL) through a review of the literature and a European survey on real-life practices for PVRL. Recent findings The care of PVRL patients is heterogeneous between specialists and countries. Upfront systemic treatment based on high-dose methotrexate chemotherapy, with or without local treatment, might reduce or delay the risk of brain relapse. Ibrutinib, lenalidomide with or without rituximab, and temozolomide are effective for patients with relapsed/refractory PVRL and should be...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Dominique Bron Source Type: research

Hairy cell leukemia: a brief update on current knowledge and treatment prospects
This article provides a brief update on the recommended diagnosis and treatment strategies for patients with the classic form of hairy cell leukemia (HCL) and HCL variant (HCLv). Recent findings HCL is a chronic B-cell malignancy with multiple treatment options. In recent years, many novel drugs have been assessed for HCL treatment with promising results. The investigated nonchemotherapy options include moxetumomab pasudotox, which targets CD22; vemurafenib or dabrafenib, which target the BRAFV600E protein; trametinib, which targets mitogen-activated protein kinase enzyme; and ibrutinib, which targets Bruton tyrosin...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Dominique Bron Source Type: research

Hepatosplenic T-cell lymphoma: treatment challenges
Purpose of review Hepatosplenic lymphoma (HSTCL) is a rare T-cell malignancy occurring in young males, associated with immune deficiency in 20% of the cases which, despite aggressive treatments, has a poor survival. Specific recommendations for first-line treatment remain debatable. Recent findings Published data covering case reports or series of HSTCL concur that allogeneic stem cell transplant should be proposed as a consolidation after response to chemotherapy in all patients eligible for transplant. In the light of two recent clinical examples, we also confirm that specific chemotherapy and a first-line con...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Dominique Bron Source Type: research

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment
Purpose of review Angioimmunoblastic T-cell lymphoma (AITL) is a frequent peripheral T-cell lymphoma affecting elderly patients with a poor outcome when treated with conventional chemotherapy. Molecular studies revealed a homogenous mutational landscape gathering anomalies in genes regulating the DNA methylation and hydroxymethylation and anomalies in T-cell signalling. Recent findings Recent studies indicate that AITL emerges from a TET2 and/or DNMT3A mutated clonal haematopoiesis. This clonal haematopoiesis bearing mutations altering DNA hydroxymethylation can explain the observed coexistence of AITL with myel...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Dominique Bron Source Type: research

Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma
Purpose of review Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived malignancy. This review aims at providing an overview of recent developments in the management of NLPHL. Recent findings Patients with stage IA NLPHL without risk factors have excellent outcomes. The 8-year progression-free survival (PFS) is roughly 90% and the 8-year overall survival (OS) close to 100% after limited-field radiotherapy (RT) alone. Individuals presenting with early stages other than stage IA without risk factors and intermediate stages have 10-year PFS rates in excess of 70% and 10-year OS rates exc...
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Dominique Bron Source Type: research

Editorial introductions
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - August 27, 2021 Category: Cancer & Oncology Tags: EDITORIAL INTRODUCTIONS Source Type: research

The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together
Purpose of review The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has become notably complex in recent years. With this review, we aimed to put the most recent findings in perspective and tried to delineate the rapidly changing treatment algorithm. Recent findings The combination of atezolizumab and bevacizumab has become the new first-line standard of care treatment for unresectable HCC after the positive results of the phase 3 IMbrave150 study. Nivolumab monotherapy failed to demonstrate advantage versus sorafenib in the CheckMate 459 trial, while two different therapeutic strategies (sint...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

State of the art and future directions in the systemic treatment of neuroendocrine neoplasms
Purpose of review Neuroendocrine neoplasms (NENs) are rare and heterogeneous malignancies whose natural evolution may be defined according to various prognostic factors, including localization of the primitive tumour, hormone secretory status, histological grade, tumour burden, tumour growth rate, expression of somatostatin receptors and fluorodeoxyglucose-avidity. The treatment of these tumours in an advanced setting is based on relatively little robust data. Recent findings A recent pathological classification introduced a new category of high-grade but well differentiated neuroendocrine tumours (NET G3), with...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials
Purpose of review To summarize current standards of care, discuss results of recent studies and present ongoing clinical trials for anal squamous cell carcinoma (ASCC). Recent findings Over the last year, no practice changing studies have been reported in the setting of localised ASCC. A number of retrospective analyses, however, have provided practice-informing data, such as those confirming the negative impact of low compliance to chemoradiotherapy (CRT) on patient outcomes. In contrast, and for the first time, randomized evidence has become available to inform the management of advanced tumours. The InterAACT...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice
Purpose of review Small bowel adenocarcinoma (SBA) is a rare disease, for which few studies have been conducted so far. Therefore, most treatment recommendations have been extrapolated from trials in colorectal cancer. In this review, we revise available data that could improve the management of SBA, with a particular focus on systemic therapy. Recent findings For advanced/irresectable disease, first-line doublet chemotherapy remains standard of care. It is uncertain whether extending treatment to triplet chemotherapy brings added benefit. Pembrolizumab is an accepted treatment modality for mismatch repair-defic...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Changes in the therapeutic landscape of oesophago-gastric cancers
This article reviews recent randomised clinical trials on systemic treatment of oesophago-gastric cancers in the perioperative and metastatic setting. Recent findings Adding nivolumab to first-line chemotherapy improved survival in patients with metastatic gastric/gastro-oesophageal junction/oesophageal adenocarcinoma with PD-L1 combined positive score (CPS) ≥ five in a global trial and progression-free survival in metastatic gastric/gastro-oesophageal junction cancers in an Asian trial. The addition of pembrolizumab to first-line chemotherapy improved survival in metastatic oesophageal cancer patients, with the ...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon
Purpose of review This review examines current developments and controversies in the multimodal management of oesophageal cancer, with an emphasis on surgical dilemmas and outcomes from the surgeon's perspective. Recent findings Despite the advancement of oncological neoadjuvant treatments, there is still no consensus on what regimen is superior. The majority of patients may still fail to respond to neoadjuvant therapy and suffer potential harm without any survival advantage as a result. In patients who do not respond, adjuvant therapy is still often recommended after surgery despite any evidence for its benefit...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research

Gynecological sarcomas: literature review of 2020
This article, focus on recently published data of the last 18 months on the management of gynecologic sarcomas. Recent findings Different tools have been studied to identify the differences between benign from malignant uterine conjonctive tumor. Molecular biology impact more and more on the diagnosis of uterine sarcoma with new definitions of very specific groups. This will make it possible to better define the last group of endometrial sarcoma which has been defined as undifferentiated. In several articles, surgical approaches and fertility-sparing surgery were described including the role of surgery for r...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

Tropomyosin receptor kinases in sarcomas – of joy and despair
Purpose of review The relatively recent discovery of neurotrophic tropomyosin receptor kinase (NTRK) gene arrangements as pan-tumor predictive biomarkers has led to impressive novel treatments for patients with TRK fusions. Although the number of patients who qualify for treatment is vanishingly small for cancer patients in general, a few histological subsets of sarcomas exhibit NTRK fusions more commonly leading to large expectations within the sarcoma community. Recent findings Larotrectenib and entrectenib have recently been approved based on durable responses in TRK positive cancers with nonresectable or met...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Purpose of review The aim is to bring latest evidence of the role of perioperative chemotherapy in localized soft-tissue sarcomas (STS) of limbs and to review the risk classification systems of retroperitoneal and extremity STS. Recent findings High-risk subset of localized STS of limbs and trunk-wall, defined with classic prognostic factors, consistently obtained 5-year overall survival ranging from 69 to 76% in randomized patients treated with full-dose of anthracycline and ifosfamide. Validated nomograms accurately predict, on individual basis, the risk of death and recurrence in localized STS of retroperiton...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

New treatments in advanced gastrointestinal stromal tumor
Purpose of review The current article revisits the most recent advances that occurred in the field of gastrointestinal stromal tumor (GIST) therapeutics. Recent findings GIST is driven by the oncogenic activation of KIT or PDGFRA receptor tyrosine kinases, and agents targeting these receptors lead to substantial benefit throughout the entire course of the disease. Two new drugs were approved in 2020. On one hand, ripretinib obtained the regulatory approval for the treatment of GIST patients after progression to all standard treatments. On the other hand, avapritinib became the first agent ever displaying activit...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

Next-generation sequencing for the management of sarcomas with no known driver mutations
Purpose of review Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer types. This review will discuss recent evidence that highlights opportunities for NGS to improve outcomes in sarcomas that have complex genomic profiles with no known driver mutations. Recent findings Global genomic signatures detectable by NGS including tumour mutational burden and microsatellite instability have potential as biomarkers for response to immunotherapy in certain sarcoma subtypes inc...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

Desmoid-type fibromatosis: toward a holistic management
Purpose of review Desmoid-type fibromatosis, a rare locally aggressive fibroblastic proliferation, is a treatment challenge. This review aimed to explore recent data about the management of desmoid-type fibromatosis. Recent findings New data underline the role of kinases and ɣ-secretase in stimulating cell proliferation and invasiveness in desmoid-type fibromatosis. This explains the proven activity of multikinase inhibitors (sorafenib or pazopanib) in the management of desmoid-type fibromatosis or the emerging role of a ɣ-secretase inhibitor. An international guideline for management was recently published, a...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program
Purpose of review The Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) is a bottom-up clinical network established in 2013 with the goal of improving the care and outcomes of patients with retroperitoneal sarcoma (RPS). Here, we review the knowledge produced by this collaborative effort and examine the future potential of this group. Recent findings TARPSWG has produced retrospective studies focused on patients with primary and recurrent RPS allowing a better understanding of patient prognosis, treatment outcomes and tumor biology. The group has played a pivotal role in a phase III rand...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research

COVID-19 and supportive cancer care: key issues and opportunities
Purpose of review The disruption to people's lives, including financial impacts, morbidity and loss of life caused by the Coronavirus disease (COVID-19) pandemic requires a dramatic transformation of cancer care delivery, including supportive care. This paper focuses on issues of supportive care in the context of the pandemic, and the extent to which these issues will impact supportive cancer care post-COVID-19. Recent findings Cancer care, including supportive care delivery, has had to be dramatically altered during the COVID-19 pandemic, including reallocation of human resources, repurposing of existing physic...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Supportive care for new cancer therapies
Purpose of review The past decade has witnessed unprecedented delivery to the clinical arena of a range of novel, innovative, and effective targeted anticancer therapies. These include immunotherapies, most prominently immune checkpoint inhibitors, as well as agents that target growth factors and cancer-related mutations. Many of these new cancer therapies are, however, associated with an array of toxicities, necessitating insight and vigilance on the part of attending physicians to achieve high-quality supportive care alongside toxicity management. In this review, we consider some of the key supportive care issues in ...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Teaching supportive care: what is the core curriculum?
Purpose of review Cancer treatment options have developed rapidly in the past years. Targeted- and immune therapy have resulted in additional supportive care needs. This review describes a teaching program in supportive care. Recent findings Supportive care begins at the time of cancer diagnosis and continues until the patient has died or is cured and late toxicities and other survivorship issues have been properly addressed. Supportive care is divided into four phases. In the curative phase, competences regarding prevention and management of acute treatment and subacute treatment side effects are important. In ...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Supportive care practice: do we need guidelines?
Purpose of review To review the role of evidence-based clinical practice guidelines in promoting the quality and consistency of supportive care in oncology to meet the needs of practitioners and patients. Recent findings To maintain quality, guidelines must be regularly updated in terms of content as new treatment modalities like immunotherapy are introduced, adapted to new methodologies such as the application of artificial intelligence, adoption of multiple symptoms or orphan symptoms and capture new endpoints such a patient-reported outcomes. This helps prevent a major barrier to implementation; negative atti...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Supportive care centers: definition of excellence
Purpose of review The current review is relevant because despite significant progress in oncology, a large proportion of patients with cancer still experience morbidity and symptoms, resulting from the cancer and/or its treatment. Recent findings The main theme concerns the definition of excellence of Supportive Care centers based on the indications of the Multinational Association Supportive Care Cancer (MASCC) because there are no data in literature on this topic. Summary Supportive care centers provide assistance to cancer patients suffering for anticancer treatments-related adverse effects. This leads...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Models of supportive care in oncology
Purpose of review Supportive care services have evolved overtime to meet the growing supportive care need of patients with cancer and their families. In this review, we summarize existing definitions of supportive care, highlight empiric studies on supportive care delivery, and propose an integrated conceptual framework on supportive cancer care. Recent findings Supportive care aims at addressing the patients’ physical, emotional, social, spiritual, and informational needs throughout the disease trajectory. Interdisciplinary teams are needed to deliver multidimensional care. Oncology teams have an importan...
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Editorial: Supportive care in cancer patients: quo vadis?
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: SUPPORTIVE CARE: Edited by Jean A. Klastersky Source Type: research

Editorial introductions
No abstract available (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - June 18, 2021 Category: Cancer & Oncology Tags: EDITORIAL INTRODUCTIONS Source Type: research

Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal
Purpose of review Present highlights from recent research examining the treatment of advanced prostate cancer. Recent findings Although debate remains about the optimal sequencing of docetaxel and novel androgen directed therapies in addition to androgen deprivation therapy (ADT) in the treatment of men with new metastatic prostate cancer, the novel LHRH antagonist relugolix seems poised to become an appealing option in a choice of initial ADT. Novel radioisotopes, genomically selected therapies, and immune therapy combinations show progress in opening up new treatment options for men with castration-resistant p...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer
Purpose of review To explore the recent advances and utility of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and risk-stratification of prostate cancer. Recent findings Low-risk, clinically insignificant prostate cancer has a decreased risk of morbidity or mortality. Meanwhile, patients with intermediate and high-risk prostate cancer may significantly benefit from interventions like radiation or surgery. To appropriately risk stratify these patients, MRI has emerged as the imaging modality in the last decade to assist in defining prostate cancer significance, location, and biologic aggress...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation
Purpose of review Although a standard of care in the treatment of organ-confined prostate cancer, use of radiation for treatment in the high-risk, metastatic and salvage settings is evolving rapidly. Recent findings Recent clinical trials have explored the role of increased treatment for high-risk disease with the addition of adjuvant chemotherapy and expanded the role of radiation in settings previously reserved for systemic therapy. Addition of adjuvant chemotherapy for high-risk prostate cancer is controversial and recent evidence is discussed that continues to refine the patient population for further evalua...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Understanding the tumor-immune microenvironment in prostate cancer
Purpose of review This review aims to highlight recent advances in prostate cancer tumor-immune microenvironment research and summarize the state-of-the-art knowledge of immune checkpoint inhibitors in prostate cancer. Recent findings Immune checkpoint inhibitors are the cornerstone of modern immunotherapy which have shown encouraging results across a spectrum of cancers. However, only limited survival benefit has been seen in patients with prostate cancer. Prostate cancer progression and its response to immunotherapies are strongly influenced by the tumor-immune microenvironment, whose feature can be summarized...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

The evolving treatment landscape of advanced urothelial carcinoma
Purpose of review Bladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC). Recent findings Since 2016, the Food and Drug Administration (FDA) has approved five immunotherapies targeting programmed cell death 1/programmed cell death 1 legend, an antinectin-4 antibody drug conjugate (ADC), and a fibroblast growth factor receptor (FGFR) inhibitor for the treatment of patients w...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma
Purpose of review As molecular profiling of renal cell carcinoma (RCC) continues to elucidate novel targets for nonclear cell histologies, understanding the landscape of these targets is of utmost importance. In this review, we highlight the genomic landscape of nonclear cell RCC and its implications for current and future systemic therapies. Recent findings Several genomic studies have described the mutational burden among nonclear cell histologies. These studies have highlighted the importance of MET in papillary RCC and led to several clinical trials evaluating the efficacy of MET inhibitors for papillary RCC...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Pearls and perils in the management of germ cell tumors
Purpose of review Research and innovation over the past half century have rendered testicular cancer a highly curable malignancy. Challenges and uncertainty remain in several aspects related to the management and surveillance of patients with germ cell tumors (GCT). Long-term effects of treatment on survivors of testicular cancer remain as continued areas of interest. This review aims to highlight pearls and perils in the management of patients with GCT. Recent findings Uncertainty remain regarding complex aspects of first-line and salvage treatments of GCT, interpretation of tumor markers in cases of α-fe...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Sinonasal cancers treatments: state of the art
Purpose of review The present review provides the reader with the state-of-the-art concepts of sinonasal oncology in view of the latest literature data. Recent findings Most recent publications in sinonasal oncology assessed treatment timing, centralization, surgical approach, margin status, orbit/neck management, salvage strategies, emerging surgical technologies, intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), particle radiotherapy, and neoadjuvant chemotherapy. Summary Indications to endoscopic surgery for sinonasal cancer have plateaued and are unlikely to furthe...
Source: Current Opinion in Oncology - April 15, 2021 Category: Cancer & Oncology Tags: HEAD AND NECK: Edited by Joël Guigay Source Type: research